Cerebrospinal fluid (CSF) samples are increasingly being used for genomic profiling of brain tumors, offering a less invasive alternative to tissue biopsies. CSF samples provide a higher signal-to-noise ratio for detecting tumor-derived cell-free DNA (cfDNA) compared to plasma samples, making them particularly useful for …
The upcoming ASCO 2026 meeting will focus on the clinical application of AI in cancer care, emphasizing multimodal AI models that integrate pathology, radiology, molecular data, and liquid biopsy.
SPONSORED ROUNDTABLES
Thermo Fisher Scientific’s SwiftArrayStudio microarray analyzer was developed in response to customer needs for simpler workflows, more consistent turnaround times, and lower operational burden in genomics labs.
CAP TODAY RECOMMENDS
February 2026—Prepared with expert insight from Anil Parwani, MD, PhD; Scott Hammond; and Melinda Schumacher, MD, Grundium’s white paper describes, from a pathologist’s perspective, how compact WSI systems can shorten consult turnaround times and reduce variability, improve access to subspecialty review without adding travel or courier burden, enhance community pathologists’ professional satisfaction and confidence, support scalable, secure, and validated workflows and lay the foundation for AI and advanced analytics as digital adoption grows. Download the white paper here.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: Billing
Laboratory and pathology billing face challenges from reimbursement threats, downcoding, denials, and prior authorizations.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
October 2023—Wren Laboratories launched its PRRT (peptide receptor radionuclide therapy) Predictor Quotient, or PPQ, a companion diagnostic to its NETest, a liquid-biopsy neuroendocrine tumor diagnostic. The test classifies patients as either a responder, a patient who will experience disease stabilization and have a longer time to disease progression (usually greater than 18 months after the end of PRRT treatment), or as a nonresponder, who will have a shorter time until the disease progresses (usually less than 12 months after the start of PRRT). According to a research paper published in April (Bodei L, et al. J Nucl Med. 2023;64[9]:1329–1330), the PPQ delivers 96 percent accuracy in determining patient response to PRRT.